The Drug Company Defeating America’s Biggest Health Crisis

October 25, 2022
Health Care

Well, now that our Merck stock pick is decidedly outperforming a shaky market, we’ve had no choice but to unleash our pharma analyst to deliver another pick for a pharma stock that just had a huge breakout.

Eli Lilly, made headlines recently when their new drug, Mounjaro, got approved for the treatment of type II diabetes. Their stock popped 4% on the news but is quickly giving that ground back thanks to a broader selloff in the S&P 500.

These gains are very small compared to the incredible growth potential Mounjaro has.

In addition to being a HUGE iterative improvement on other Type-II Diabetes treatments, Mounjaro is currently demonstrating REMARKABLE efficacy for treating obesity.  

Obesity is slowly replacing heart disease as the definitive health crisis in America. Treating obesity has been really hard outside of diet, exercise, and invasive surgeries. If Mounjaro’s current results hold, it will corner two high-revenue markets simultaneously.

Mounjaro is a Diabetes Game-Changer:

While they’ve managed to grow revenue by 15% in Q1, the future of the company could rest on this drug.

So, let’s get into it 👇

Start your investment journey

Scan to download Moby

Scan to download Moby

Annual

Want the full Moby experience? Our annual premium offers news, alerts, earnings, IPO calendars and more, including the Ultimate Investing Course (at a value of $99.99USD) to help you invest smarter. Save 45% with our Annual Premium – billed at $199.95 USD/year.

$0 / 7days

$16.66 USD/month

Download for Free

Monthly

Ready to start making better investment decisions? Join our monthly premium today with access to research, reports, and more for only $29.95USD.

$29.95 / month

+ processing fees

Try Monthly